A new study reveals that obesity accelerated Alzheimer's blood biomarkers by 95% over five years, highlighting a strong ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...

Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse Alzheimer's disease, the number one cause of dementia.

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

As Alzheimer’s Awareness Month comes to an end, Florida State University researchers are continuing efforts to better ...

Researchers found long-term treatment could delay progression from mild cognitive impairment to moderate Alzheimer’s disease ...

Down syndrome is caused by an extra copy of chromosome 21. Because of genes present on this chromosome that are known to ...

Researchers have conducted the first study evaluating the impact of obesity on Alzheimer's disease blood biomarkers (BBMs).